Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report

Descripción del Articulo

Irreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovi...

Descripción completa

Detalles Bibliográficos
Autores: Lechuga-Noa, Víctor E., Rodríguez-Tanta, L. Yesenia, Solis-Yucra, Tania del Pilar, Rojo Rosales, Efraín Cesar
Formato: artículo
Fecha de Publicación:2025
Institución:Instituto Nacional Cardiovascular
Repositorio:Archivos peruanos de cardiología y cirugía cardiovascular
Lenguaje:inglés
OAI Identifier:oai:apcyccv.org.pe:article/456
Enlace del recurso:https://apcyccv.org.pe/index.php/apccc/article/view/456
Nivel de acceso:acceso abierto
Materia:Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
id REVINCOR_35e3f685ea147ac6198ebcb96425b1f3
oai_identifier_str oai:apcyccv.org.pe:article/456
network_acronym_str REVINCOR
network_name_str Archivos peruanos de cardiología y cirugía cardiovascular
repository_id_str
dc.title.none.fl_str_mv Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
title Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
spellingShingle Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
Lechuga-Noa, Víctor E.
Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
title_short Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
title_full Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
title_fullStr Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
title_full_unstemmed Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
title_sort Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
dc.creator.none.fl_str_mv Lechuga-Noa, Víctor E.
Rodríguez-Tanta, L. Yesenia
Solis-Yucra, Tania del Pilar
Rojo Rosales, Efraín Cesar
Lechuga-Noa, Víctor E.
Rodríguez-Tanta, L. Yesenia
Solis-Yucra, Tania del Pilar
Rojo Rosales, Efraín Cesar
author Lechuga-Noa, Víctor E.
author_facet Lechuga-Noa, Víctor E.
Rodríguez-Tanta, L. Yesenia
Solis-Yucra, Tania del Pilar
Rojo Rosales, Efraín Cesar
author_role author
author2 Rodríguez-Tanta, L. Yesenia
Solis-Yucra, Tania del Pilar
Rojo Rosales, Efraín Cesar
author2_role author
author
author
dc.subject.none.fl_str_mv Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
topic Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
Breast Neoplasms
Cardiotoxicity
Trastuzumab
Pharmacovigilance
description Irreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovigilance case of longterm IC and conducted a systematic review (SR) of the clinical manifestations of cases reported worldwide. We reported the case using the CARE guidelines checklist and assessed the causality using the modified Algorithm of Karch and Lasagna. Following PRISMA guidelines, we conducted the SR using defined terms in PubMed, Embase, Scopus, and Web of Science from inception until June 2023. This SR included five case reports, including the pharmacovigilance case reported by us. While patients exhibited different severe clinical characteristics, receiving TZB at a 6 mg/kg dose was consistent. Despite varying treatment durations, the median time of IC diagnosis was 10 months, and the average difference between the basal and the final left ventricular ejection fraction was roughly 30%. According to the modified Karch and Lasagna algorithm, all cases were ranged from possible to probable. While TZB is generally considered a reversible cardiotoxic antineoplastic, clinicians and regulators must be aware of the potential IC risk with long-term manifestations. Vigilant cardiac monitoring and further research are crucial to better understanding and managing this serious adverse event.
publishDate 2025
dc.date.none.fl_str_mv 2025-03-21
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-Review article
Artículo evaluado por pares
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://apcyccv.org.pe/index.php/apccc/article/view/456
10.47487/apcyccv.v6i1.456
url https://apcyccv.org.pe/index.php/apccc/article/view/456
identifier_str_mv 10.47487/apcyccv.v6i1.456
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://apcyccv.org.pe/index.php/apccc/article/view/456/615
https://apcyccv.org.pe/index.php/apccc/article/view/456/616
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo” – INCOR, EsSalud
publisher.none.fl_str_mv Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo” – INCOR, EsSalud
dc.source.none.fl_str_mv Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 No. 1 (2025); 1-10
Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 Núm. 1 (2025); 1-10
2708-7212
10.47487/apcyccv.v6i1
reponame:Archivos peruanos de cardiología y cirugía cardiovascular
instname:Instituto Nacional Cardiovascular
instacron:INCOR
instname_str Instituto Nacional Cardiovascular
instacron_str INCOR
institution INCOR
reponame_str Archivos peruanos de cardiología y cirugía cardiovascular
collection Archivos peruanos de cardiología y cirugía cardiovascular
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1844898426971488256
spelling Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case reportIrreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case reportLechuga-Noa, Víctor E.Rodríguez-Tanta, L. YeseniaSolis-Yucra, Tania del PilarRojo Rosales, Efraín CesarLechuga-Noa, Víctor E.Rodríguez-Tanta, L. YeseniaSolis-Yucra, Tania del PilarRojo Rosales, Efraín CesarBreast NeoplasmsCardiotoxicityTrastuzumabPharmacovigilanceBreast NeoplasmsCardiotoxicityTrastuzumabPharmacovigilanceIrreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovigilance case of longterm IC and conducted a systematic review (SR) of the clinical manifestations of cases reported worldwide. We reported the case using the CARE guidelines checklist and assessed the causality using the modified Algorithm of Karch and Lasagna. Following PRISMA guidelines, we conducted the SR using defined terms in PubMed, Embase, Scopus, and Web of Science from inception until June 2023. This SR included five case reports, including the pharmacovigilance case reported by us. While patients exhibited different severe clinical characteristics, receiving TZB at a 6 mg/kg dose was consistent. Despite varying treatment durations, the median time of IC diagnosis was 10 months, and the average difference between the basal and the final left ventricular ejection fraction was roughly 30%. According to the modified Karch and Lasagna algorithm, all cases were ranged from possible to probable. While TZB is generally considered a reversible cardiotoxic antineoplastic, clinicians and regulators must be aware of the potential IC risk with long-term manifestations. Vigilant cardiac monitoring and further research are crucial to better understanding and managing this serious adverse event.Irreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovigilance case of longterm IC and conducted a systematic review (SR) of the clinical manifestations of cases reported worldwide. We reported the case using the CARE guidelines checklist and assessed the causality using the modified Algorithm of Karch and Lasagna. Following PRISMA guidelines, we conducted the SR using defined terms in PubMed, Embase, Scopus, and Web of Science from inception until June 2023. This SR included five case reports, including the pharmacovigilance case reported by us. While patients exhibited different severe clinical characteristics, receiving TZB at a 6 mg/kg dose was consistent. Despite varying treatment durations, the median time of IC diagnosis was 10 months, and the average difference between the basal and the final left ventricular ejection fraction was roughly 30%. According to the modified Karch and Lasagna algorithm, all cases were ranged from possible to probable. While TZB is generally considered a reversible cardiotoxic antineoplastic, clinicians and regulators must be aware of the potential IC risk with long-term manifestations. Vigilant cardiac monitoring and further research are crucial to better understanding and managing this serious adverse event.Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo” – INCOR, EsSalud2025-03-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-Review articleArtículo evaluado por paresapplication/pdfapplication/pdfhttps://apcyccv.org.pe/index.php/apccc/article/view/45610.47487/apcyccv.v6i1.456Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 No. 1 (2025); 1-10Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 Núm. 1 (2025); 1-102708-721210.47487/apcyccv.v6i1reponame:Archivos peruanos de cardiología y cirugía cardiovascularinstname:Instituto Nacional Cardiovascularinstacron:INCORenghttps://apcyccv.org.pe/index.php/apccc/article/view/456/615https://apcyccv.org.pe/index.php/apccc/article/view/456/616Derechos de autor 2025 La revista es titular de la primera publicación, luego el autor dando crédito a la primera publicación.https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:apcyccv.org.pe:article/4562025-06-23T23:12:10Z
score 12.615219
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).